31199-03-8

Upstream product

• 67-56-1 methanol 
• 58953-12-1 (E)-1-chloropent-1-en-3-one 
• 107-31-3 Methyl formate 
• 78-93-3 butanone 
• 14674-62-5 1-methoxy-pent-1-en-3-yne 
• 56699-03-7 1-methoxy-3-methylsulfanyl-penta-1,2-diene 
• 593-60-2 Vinyl bromide 
• 124-41-4 sodium methylate 
• 79-03-8 propionyl chloride 
• 6651-40-7 2-(trimethylsilyloxy)-1-butene 
• 149-73-5 trimethyl orthoformate 
• 18387-58-1 1-(trimethylsilyl)-1-pentyne-3-one 

Downstream Products

• 14269-18-2 3-ethyl-1-(4-nitro-phenyl)-1H-pyrazole 
• 14269-17-1 5-ethyl-1-(4-nitro-phenyl)-1H-pyrazole 
• 1576-87-0 trans-2-pentenal 
• 939-27-5 2-ethylnaphthalene 
• 704913-84-8 3-ethyl-furan-2-carboxylic acid methyl ester 
• 436143-81-6 (1R,2S,5R,7R)-2-methyl-7-phenyl-6,8-dioxabicyclo[3.2.1]octan-3-one 
• 98134-79-3 1-(2-amino-thiazol-5-yl)-propan-1-one 
• 5896-50-4 1-(4-ethyl-2-hydroxyphenyl)-ethanone 
• 1189819-99-5 C₁₂H₁₆O₂ 
• 1189819-98-4 1-(6-ethyl-2-hydroxy-3-methylphenyl)propan-1-one 
• 1189819-97-3 (2-ethyl-6-hydroxyphenyl)phenylmethanone 
• 78473-50-4 4-Aethyl-2-hydroxy-benzophenon 
• 71539-38-3 4-ethyl-2-hydroxybenzoic acid ethyl ester 
• 82064-77-5 2-ethyl-6-hydroxybenzoic acid ethyl ester 

Relevant academic research and scientific papers

Catalytic asymmetric hydrogenation of pyrimidines

The asymmetric hydrogenation of pyrimidines proceeded with high enantioselectivity (up to 99% ee) using an iridium catalyst composed of [IrCl(cod)]2, a ferrocene-containing chiral diphosphine ligand (Josiphos), iodine, and Yb(OTf)3 (cod=1,5-cyclooctadiene). The chiral catalyst converted various 4-substituted pyrimidines into chiral 1,4,5,6-tetrahydropyrimidines in high yield. The lanthanide triflate is crucial for achieving the high enantioselectivity as well as for activating the heteroarene substrate.

FE(III) COMPLEX COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF IRON DEFICIENCY SYMPTOMS AND IRON DEFICIENCY ANEMIAS

The invention relates to iron(III) complex compounds and pharmaceutical compositions comprising them for the use as medicaments, in particular for the treatment and/or prophylaxis of iron deficiency symptoms and iron deficiency anemias.

PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS

The invention relates to pyrimidin-2-one compounds of general formula (I), in addition to the derivatives and tautomers of (I) and the physiologically acceptable salts of said compounds. In said formula: A represents linear or branched C3-C6 alkene, which can have a double bond or triple bond and/or a group Z, which is not adjacent to the nitrogen atom of the pyrimidinone ring and is selected from O, S, C(O), NR3, C(O)NR3, NR3C(O), OC(O) and C(O)O; B represents a group of formula (II), in which X stands for CH2 or N and Y stands for CH2 or CH2CH2, or X-Y can also jointly represent C=CH, C=CH-CH2 or CH-CH=CH; R1 and R 2 are defined as cited in the description and the claims; and Ar represents an optionally substituted aromatic group. The invention also relates to a pharmaceutical agent, containing at least one compound (I) and the tautomers, derivatives and/or acid addition salts of said compound, optionally together with physiologically acceptable carriers and/or auxiliary agents. The invention also relates to the use of compounds of formula (I), and their tautomers, derivatives and pharmacologically acceptable acid addition salts for producing a pharmaceutical agent for treating diseases, which respond to the influence of dopamine D3 receptor ligands.

Intramolecular TiCl4-mediated cyclization reaction of β-hydroxyalkynyl acetals

Intramolecular TiCl4-mediated cyclization reaction of 1,1-dimethoxy-3-hydroxy-hex-5-yne derivatives produced anti-1-hydroxy-3-methoxy-cyclohex-5-ene derivatives with high diastereoselectivity via antiperiplanar manner on pseudo six-membered chair like conformation (transition state A).

Stereospecific synthesis of cryptophycin 1

Matrix presented A brief stereospecific synthesis of cryptophycin 1 is described in which (R)-mandelic acid serves as the sole source of asymmetry for unit A. The key step is a hetero-Diels-Alder cycloaddition.